Viral hepatitis is a central concept within medical and public health research, defining the condition of liver inflammation caused by specific viral pathogens. This research area encompasses the study of the causative viruses, their pathogenesis, clinical outcomes, diagnostic methods, therapeutic interventions, prevention strategies, and global epidemiological patterns.
Ontological type
Etiologic viruses
Therapeutics and prevention
Pathogenesis and immunology
Epidemiology and Immunoprophylaxis
1945 - 1968
Molecular Serology and Genomics
1969 - 1997
Antivirals and Host-Directed Therapies
1998 - 2024
Epidemiology and Immunoprophylaxis era
Saul Krugman [1] was a leading figure in hepatitis research during the Epidemiology and Immunoprophylaxis era (1945-1968), with affiliations at the United States Military Academy [2] and Kettering University [3]. His 1959 paper Infectious Hepatitis [4] helped redefine the epidemiology of hepatitis by clarifying transmission patterns and underscoring the value of population-level surveillance and outbreak management, thereby underpinning the era's emphasis on immunoprophylaxis, donor screening, and public health interventions.
Molecular Serology and Genomics era
Michael Houghton [1] emerges as a pivotal figure in the Molecular Serology and Genomics era, with research spanning institutions such as the University of California, San Francisco [3] and the University of Hong Kong [4]. His work includes the isolation of a cDNA clone derived from a blood-borne non-A, non-B hepatitis genome [7], the framing of hepatitis C virus biology for diagnosis, development and control [8], and the identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end [9], advances that provided molecular targets for diagnostics and epidemiologic tracking in this era. Thierry Poynard [2] is likewise a central figure, with affiliations at Northwestern University [5] and Yale University [6] reflecting a cross-institutional footprint during this era. His sole highlighted contribution in the era is the 1996 paper An Algorithm for the Grading of Activity in Chronic Hepatitis C [10], which established standardized activity scoring that improved comparability across studies and informed clinical assessment and management.
Antivirals and Host-Directed Therapies era
John G. McHutchison [1] is a leading figure in the Antivirals and Host-Directed Therapies era, with affiliations at Harvard University [3] and the University of California, San Francisco [4] during this period. His work on peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C established standard regimens and informed resistance profiling, as shown in the 2001 randomized trial [7], and the discovery that IL28B genetic variation predicts hepatitis C treatment-induced viral clearance [8] and spontaneous clearance [9], signaling a pivotal move toward host-directed predictors in this era. Janice K. Albrecht [2] is a prominent figure connected with University of Pennsylvania [5] and Sorbonne Université [6] during this era. Her contributions to optimizing interferon-based regimens, including the 1998 randomized trial [10], and the 2001 peginterferon alfa-2b plus ribavirin trial [7], advanced treatment duration decisions and patient stratification, helping to lay groundwork for later antiviral strategies.